GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (WBO:LLYC) » Definitions » Cyclically Adjusted PS Ratio

Eli Lilly and Co (WBO:LLYC) Cyclically Adjusted PS Ratio : 26.34 (As of Apr. 29, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Eli Lilly and Co Cyclically Adjusted PS Ratio?

As of today (2024-04-29), Eli Lilly and Co's current share price is €688.60. Eli Lilly and Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was €26.14. Eli Lilly and Co's Cyclically Adjusted PS Ratio for today is 26.34.

The historical rank and industry rank for Eli Lilly and Co's Cyclically Adjusted PS Ratio or its related term are showing as below:

WBO:LLYC' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.48   Med: 4.9   Max: 27.17
Current: 25.42

During the past years, Eli Lilly and Co's highest Cyclically Adjusted PS Ratio was 27.17. The lowest was 2.48. And the median was 4.90.

WBO:LLYC's Cyclically Adjusted PS Ratio is ranked worse than
98.51% of 739 companies
in the Drug Manufacturers industry
Industry Median: 2.09 vs WBO:LLYC: 25.42

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Eli Lilly and Co's adjusted revenue per share data for the three months ended in Dec. 2023 was €9.490. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €26.14 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eli Lilly and Co Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Eli Lilly and Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Cyclically Adjusted PS Ratio Chart

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.92 7.43 11.14 13.57 20.20

Eli Lilly and Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.57 12.48 16.73 18.76 20.20

Competitive Comparison of Eli Lilly and Co's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted PS Ratio falls into.



Eli Lilly and Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Eli Lilly and Co's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=688.60/26.14
=26.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Eli Lilly and Co's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=9.49/129.4194*129.4194
=9.490

Current CPI (Dec. 2023) = 129.4194.

Eli Lilly and Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 3.147 99.695 4.085
201406 3.375 100.560 4.344
201409 3.521 100.428 4.537
201412 3.881 99.070 5.070
201503 4.022 99.621 5.225
201506 4.163 100.684 5.351
201509 4.149 100.392 5.349
201512 4.634 99.792 6.010
201603 4.110 100.470 5.294
201606 4.538 101.688 5.776
201609 4.361 101.861 5.541
201612 5.132 101.863 6.520
201703 4.628 102.862 5.823
201706 4.904 103.349 6.141
201709 4.495 104.136 5.586
201712 2.642 104.011 3.287
201803 3.835 105.290 4.714
201806 4.641 106.317 5.649
201809 4.431 106.507 5.384
201812 4.852 105.998 5.924
201903 4.580 107.251 5.527
201906 5.395 108.070 6.461
201909 5.414 108.329 6.468
201912 6.010 108.420 7.174
202003 5.817 108.902 6.913
202006 5.361 108.767 6.379
202009 5.348 109.815 6.303
202012 6.689 109.897 7.877
202103 6.266 111.754 7.256
202106 6.145 114.631 6.938
202109 6.321 115.734 7.068
202112 7.648 117.630 8.415
202203 7.824 121.301 8.348
202206 6.798 125.017 7.037
202209 7.757 125.227 8.017
202212 7.617 125.222 7.872
202303 7.197 127.348 7.314
202306 8.499 128.729 8.545
202309 9.891 129.860 9.857
202312 9.490 129.419 9.490

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eli Lilly and Co  (WBO:LLYC) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Eli Lilly and Co Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co (WBO:LLYC) Business Description

Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Eli Lilly and Co (WBO:LLYC) Headlines

No Headlines